cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cogent Biosciences Inc
4 own
3 watching
Current Price
$15.5
$0.32
(2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,082.8M
52-Week High
52-Week High
18.07
52-Week Low
52-Week Low
3.79
Average Volume
Average Volume
0.57M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-6.94029851
iconMarket Capitalization1,082.8M
icon52-Week High18.07
icon52-Week Low3.79
iconAverage Volume0.57M
iconDividend Yield--
iconP/E Ratio-6.94029851
What does the Cogent Biosciences Inc do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cogent Biosciences Inc make?
News & Events about Cogent Biosciences Inc.
Globe Newswire
2days ago
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will ...
Globe Newswire
25days ago
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2nd-line Gastrointestinal ...
Globe Newswire
29days ago
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present at ...
Globe Newswire
2 months ago
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Cogent Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Cogent Biosciences Inc shares?
plus_minus_icon
How can I buy Cogent Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Cogent Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cogent Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Cogent Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Cogent Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cogent Biosciences Inc?
plus_minus_icon
What percentage is Cogent Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cogent Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$15.5
$0.32
(2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00